Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study

Rienzo, V. Di; Cadario, G; Grieco, Teresa; Galluccio, A.; Caffarelli, Carlo; Liotta, Giuseppe; Pecora, S; Burastero, Samuele E.

doi:10.1016/j.anai.2014.09.009

Cited by 44 publications

(52 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to systematic reviews and meta‐analyses, SCIT is helpful in alleviating symptoms and reducing medication in patients with allergic rhinoconjunctivitis and allergic asthma, whereas its benefits for atopic dermatitis (AD) are still unclear . However, some clinical trials and reports of AD patient experience have been highly encouraging . Sublingual, intralymphatic and epicutaneous immunotherapy have also been evaluated.…”

Section: Allergen Immunotherapy (Ait) From Human Beings To Animalsmentioning

confidence: 99%

Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs

Mueller¹,

Jensen‐Jarolim

Roth‐Walter

et al. 2018

Allergy

View full text Add to dashboard Cite

In human patients with seasonal allergic rhinoconjunctivitis sensitized to grass pollen, the first successful allergen immunotherapy (AIT) was reported in 1911. Today, immunotherapy is an accepted treatment for allergic asthma, allergic rhinitis and hypersensitivities to insect venom. AIT is also used for atopic dermatitis and recently for food allergy. Subcutaneous, epicutaneous, intralymphatic, oral and sublingual protocols of AIT exist. In animals, most data are available in dogs where subcutaneous AIT is an accepted treatment for atopic dermatitis. Initiating a regulatory response and a production of "blocking" IgG antibodies with AIT are similar mechanisms in human beings and dogs with allergic diseases. Although subcutaneous immunotherapy is used for atopic dermatitis in cats, data for its efficacy are sparse. There is some evidence for successful treatment of feline asthma with AIT. In horses, most studies evaluate the effect of AIT on insect hypersensitivity with conflicting results although promising pilot studies have demonstrated the prophylaxis of insect hypersensitivity with recombinant antigens of biting midges (Culicoides spp.). Optimizing AIT using allergoids, peptide immunotherapy, recombinant allergens and new adjuvants with the different administration types of allergen extracts will further improve compliance and efficacy of this proven treatment modality.

show abstract

Section: Allergen Immunotherapy (Ait) From Human Beings To Animalsmentioning

confidence: 99%

Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs

Mueller¹,

Jensen‐Jarolim

Roth‐Walter

et al. 2018

Allergy

View full text Add to dashboard Cite

show abstract

“…Live virus or bacterial vac-tions are the major focus of published clinical trials for oral mucosal vaccination. [580][581][582][583] There are few clinical data on traditional prophylactic vaccines delivered via the SL or buccal route, although studies are registered on ClinicalTrials.gov for influenza, cholera, and HPV. 584,585 Preclinical studies of SL vaccines have demonstrated immunogenicity in mice using viral vectors such as adenovirus-based vaccines [586][587][588] and bacterial vectors such as Bacillus subtilis.…”

Section: Challenges For Mucosal Delivery Of Vaccinesmentioning

confidence: 99%

Technologies to Improve Immunization

Papania¹,

Zehrung²,

Jarrahian³

2018

Plotkin's Vaccines

View full text Add to dashboard Cite

“…The bulk of evidence for the effectiveness of ASIT in humans is for the management of allergic rhinitis and asthma; in fact, some authorities have considered its usefulness in human AD to be questionable. On the one hand, this position has been reinforced by systematic reviews concluding that that the strength of recommendation for use of ASIT in human AD is weak; on the other, some clinical trials and reports of patient experience have been highly encouraging, even in refractory cases …”

Section: Introduction: Why Allergen‐specific Immunotherapy?mentioning

confidence: 96%

“…On the one hand, this position has been reinforced by systematic reviews concluding that that the strength of recommendation for use of ASIT in human AD is weak; 3 on the other, some clinical trials and reports of patient experience have been highly encouraging, even in refractory cases. [4][5][6] In dogs, this controversy seemingly never arose, perhaps due to early reports of success in CAD; as even in a placebo-controlled trial, results provided initial reason for optimism in allergic skin disease. [7][8][9] Based on these and other studies, "response rates" (typically quoted as percentage of dogs that experience at least 50% improvement in clinical signs) are typically quoted as 60-70%.…”

mentioning

confidence: 99%

The future of immunotherapy for canine atopic dermatitis: a review

DeBoer

2017

Veterinary Dermatology

View full text Add to dashboard Cite

Allergen specific immunotherapy (ASIT) is a foundation treatment for canine atopic dermatitis (CAD), though few critical studies have documented its effectiveness as a disease-modifying treatment in dogs. The mechanisms by which ASIT works in dogs have not been elucidated, although they are likely to parallel those known for humans. Current ASIT approaches in CAD focus on either subcutaneous or sublingual administration. Greater knowledge of major allergens in dogs, ideal dosage regimes and details of allergen admixture are likely to lead to better efficacy in CAD. Evaluation of biomarkers for successful therapy may also be of benefit. Potentially important advances in human medicine, that have yet to be explored in dogs, include use of modified allergen preparations such as allergoids, recombinant major allergens or allergen peptides; modification with adjuvants; or packaging of the above in virus-like particles. Co-administration of immunomodulators such as CpG oligodeoxynucleotides or specific monoclonal antibodies might direct the immune response in the desired direction while calming the "cytokine storm" of active disease. Initial trials of alternative routes of administration such as intralymphatic immunotherapy have yielded exciting results in humans, and continuing study in dogs is underway. Progress in ASIT of human food allergy may provide clues that will assist with improved diagnosis and patient management of CAD. Importantly, further study must be undertaken to clarify the conditions under which ASIT is a valuable treatment modality for dogs.

show abstract

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study

Cited by 44 publications

References 10 publications

Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs

Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs

Technologies to Improve Immunization

The future of immunotherapy for canine atopic dermatitis: a review

Contact Info

Product

Resources

About